<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797780</url>
  </required_header>
  <id_info>
    <org_study_id>SY-1425-301</org_study_id>
    <secondary_id>2020-004528-40</secondary_id>
    <nct_id>NCT04797780</nct_id>
  </id_info>
  <brief_title>SY-1425 Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients With Higher-risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syros Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syros Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the efficacy of SY-1425 in combination with azacitidine to azacitidine in&#xD;
      combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA)&#xD;
      positive, and newly diagnosed with higher-risk myelodysplastic syndrome (MDS), and who have&#xD;
      not received treatment for this diagnosis. The primary goal of the study is to compare the&#xD;
      complete remission rate between the two treatment arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A subset of participants have MDS characterized by an overexpression of the RARA gene. A&#xD;
      blood test will be used to identify participants with RARA-positive MDS. Assessment of the&#xD;
      RARA biomarker for study eligibility will be done by collection of blood samples from&#xD;
      potential study participants at the pre-screening visit and testing at a central laboratory.&#xD;
      Participants who meet eligibility requirements will be randomized 2:1 to receive either&#xD;
      SY-1425 plus azacitidine or placebo plus azacitidine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">February 8, 2029</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with Complete Remission</measure>
    <time_frame>Up to 5 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieve Objective Response</measure>
    <time_frame>Up to 5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Event Free Survival</measure>
    <time_frame>Up to 5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Survival</measure>
    <time_frame>Up to 5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieve Transfusion Independence</measure>
    <time_frame>Up to 5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete Response</measure>
    <time_frame>Up to 5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response</measure>
    <time_frame>Up to 5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Remission</measure>
    <time_frame>Up to 5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Initial Response</measure>
    <time_frame>Up to 5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Adverse Events and Serious Adverse Events</measure>
    <time_frame>Up to 5 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>SY-1425 + Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SY-1425: 6 mg administered orally twice per day (BID) on Days 8 through 28 of each 28-day treatment cycle.&#xD;
Azacitidine: 75 mg/m^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-1425 Matched Placebo + Azacitidine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: SY-1425-matching tablets administered orally BID on Days 8 through 28 of each 28-day treatment cycle.&#xD;
Azacitidine: 75 mg/m^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-1425 + Azacitidine</intervention_name>
    <description>SY-1425 will be administered at 6 mg twice per day (BID) (orally) each day on Days 8 through 28 of each 28-day treatment cycle (total daily dose of 12 mg).&#xD;
Azacitidine will be administered at 75 mg/m2 (intravenously or subcutaneously) each day on Days 1 through 7 of each 28-day treatment cycle. If dosing on Days 6 and 7 is not possible due to logistical limitations, these doses may be delayed to Days 8 and 9. SY-1425/placebo is permitted to overlap with azacitidine on Days 8 through 9 of this alternative schedule.</description>
    <arm_group_label>SY-1425 + Azacitidine</arm_group_label>
    <other_name>Tamibarotene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-1425 Matched Placebo + Azacitidine</intervention_name>
    <description>SY-1425 matched placebo will be administered at twice per day (BID) (orally) each day on Days 8 through 28 of each 28-day treatment cycle.&#xD;
Azacitidine will be administered at 75 mg/m2 (intravenously or subcutaneously) each day on Days 1 through 7 of each 28-day treatment cycle. If dosing on Days 6 and 7 is not possible due to logistical limitations, these doses may be delayed to Days 8 and 9. SY-1425/placebo is permitted to overlap with azacitidine on Days 8 through 9 of this alternative schedule.</description>
    <arm_group_label>SY-1425 Matched Placebo + Azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Participants must be at least 18 years old at the time of signing of an informed&#xD;
             consent.&#xD;
&#xD;
          2. Participants must be RARA-positive based on the investigational assay.&#xD;
&#xD;
          3. Participants must be newly diagnosed with HR-MDS as follows:&#xD;
&#xD;
             Diagnosis of MDS according to the World Health Organization (WHO) classification&#xD;
             (Arber 2016) and classified by the Revised International Prognostic Scoring System&#xD;
             (IPSS R) risk category as very high, high, or intermediate risk.&#xD;
&#xD;
          4. Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of&#xD;
             â‰¤2.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Participants are suitable for and agree to undergo allogeneic HSCT at the time of&#xD;
             Screening.&#xD;
&#xD;
          2. Participants who received prior treatment for MDS with any hypomethylating agent,&#xD;
             chemotherapy or allogeneic HSCT.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Syros Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>617-865-4664</phone>
    <email>schintakindi@syros.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Director</last_name>
    <phone>: 617-674-9119</phone>
    <email>mkelly@syros.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Deepa Jeyakumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Casey O'Connell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angelas</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Wanxing Chai Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center, Inc</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jason Tache</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Hematology and Oncology</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Archana Pathak</last_name>
      <phone>727-384-4388</phone>
      <email>apathak@comphemonc.com</email>
    </contact>
    <investigator>
      <last_name>Pratibha Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Syed Abid</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Faseeb Khaja</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neeharika Makani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olesea Bonanno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Trevor Feinstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Parrott</last_name>
      <email>Karen-parrott@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eric Jacobsen</last_name>
      <email>Erin-Frimml@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Grerk Sutamtewagul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laura Finn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colin Huck</last_name>
      <phone>410-614-3725</phone>
    </contact>
    <investigator>
      <last_name>Amy DeZern</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland, PA</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ralph Vincent Boccia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc.</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ira Oliff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCL Health Research Institute, Inc. (St. Vincent Frontier Cancer Center)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patrick Cobb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Troy Fiddler</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Christianson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>11102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aditi Shastri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melina Sharif</last_name>
      <email>sharifm@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Jenna Thomas</last_name>
      <email>thomasj21@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Hetty Carraway</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anjali Advani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Betty Hamilton</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jarislow Meciejewski</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Afaf Osman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabrina Costantini</last_name>
      <email>sabrina.costantini@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Chloe Spilleboudt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de LiÃ¨ge</name>
      <address>
        <city>LiÃ¨ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CÃ©line Faccinetto</last_name>
      <phone>+32-4-366 82 51</phone>
      <email>cfaccinetto@chuliege.be</email>
    </contact>
    <investigator>
      <last_name>Marie Lejeune</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amandine Hubert</last_name>
      <phone>+ 33 3 22 45 54 23</phone>
      <email>hubert.amandine@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Delphine Lebon</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magalie Joris</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lavinia Merlusca</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Paubelle</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melanie Le Van Suu</last_name>
      <phone>+33(0)2 41 35 67 26</phone>
      <email>Melanie.levansuu@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain Thepot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la CÃ´te Basque HÃ©matologie Clinique</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SÃ©verine Labarrere</last_name>
      <phone>+33 5 59 44 38 28</phone>
      <email>slabarrere@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Baptiste Perrard</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carla Araujo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Banos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Gay</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geoffrey Edouart</last_name>
      <phone>+33-1-48-95-75-05 or +33-1-48</phone>
      <email>geoffrey.edouart@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Thorsten Braun</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine Brechignac</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Ivanoff</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justine Siavellis</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de BREST - HÃ´pital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romuald Kerdoncuff</last_name>
      <phone>33.2.29.02.01.00</phone>
      <email>romuald.kerdoncuff@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>GaÃ«lle Guillerm</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe Ianotto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Anne Couturier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Celine Constant</last_name>
      <phone>+33 1 39 23 97 83</phone>
      <email>cconstant@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Rousselot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bettina Viel</last_name>
      <phone>+33 2 40 08 32 60</phone>
      <email>bettina.viel@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>LÃ©a Robert</last_name>
      <phone>+33 2 40 08 32 60</phone>
      <email>Lea.robet@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alice Garnier</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice Chevallier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxine Jullien</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry Guillaume</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hopital L'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas Cluzeau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hajer Chehimi</last_name>
      <phone>+33 1 71 20 70 10</phone>
      <email>hajer.chehimi@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Fenaux</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel Ades</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorea Aguinaga</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Drevon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Quesada</last_name>
      <phone>+33 (0)4 68 61 89 02</phone>
      <email>kevin.quesada@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Sanhes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corentin Rouvray</last_name>
      <phone>+33(0)5 24 54 91 69</phone>
      <email>corentin.rouvray@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Dimicoli-Salazar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Leclercq</last_name>
      <phone>+33 4 78 86 22 69</phone>
      <email>sophie.leclercq@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>GaÃ«lle Fossard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poiters</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Achiath Lassissi</last_name>
      <phone>+33 549443115</phone>
      <email>achiath.lassissi@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jose Torregrosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICANS Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camille Collin</last_name>
      <phone>+33(0)3 68 76 72 03</phone>
      <email>c.collin@icans.eu</email>
    </contact>
    <investigator>
      <last_name>Celestine Simand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louiza Bennane</last_name>
      <email>Louiza.BENNANE@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>StÃ©phane De Botton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Romagnolo Institute to Study Tumors &quot;Dino Amadori &quot;/ Meldona</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giovanni Marconi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giulia Tolomelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³n Privada Instituto de InvestigaciÃ³n OncolÃ³gica Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Valcarcel-Ferreiras</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>IÃ±aki JimÃ©nez GÃ³mez</last_name>
      <phone>+34 93 556 5520</phone>
      <email>IJimenezG@santpau.ca</email>
    </contact>
    <investigator>
      <last_name>Ana Garrido</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Belen Veldhuizen Vaquero</last_name>
      <phone>+34 91 550 48 00</phone>
      <phone_ext>3750</phone_ext>
      <email>belen.veldhuizen@quironsalud.es</email>
    </contact>
    <contact_backup>
      <last_name>Arantxa Garcia Raso</last_name>
      <phone>+34 91 550 48 00</phone>
      <phone_ext>3719</phone_ext>
      <email>argarciar@quironsalud.es</email>
    </contact_backup>
    <investigator>
      <last_name>Teresa Arquero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raquel Gil Ortega</last_name>
      <phone>+34 91 207 12 47</phone>
      <email>raquelhematologia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Raquel De Paz Arias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturia</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Garcia</last_name>
      <phone>'+34 669 204 799</phone>
      <email>neohem@ispasturias.es</email>
    </contact>
    <investigator>
      <last_name>Teresa Bernal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josep BorrÃ s Vives</last_name>
      <phone>+34 871 202158</phone>
      <email>jborras@hsll.es</email>
    </contact>
    <contact_backup>
      <last_name>Magdalena Flexas Morey</last_name>
      <email>m.flexas@ssib.es</email>
    </contact_backup>
    <investigator>
      <last_name>Juan JosÃ© Bargay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ana Alfonso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magdalena Garcia</last_name>
      <phone>+34 923291100</phone>
      <phone_ext>55974</phone_ext>
      <email>mgarcia.ibsal@saludcastillayleon.es</email>
    </contact>
    <investigator>
      <last_name>Maria Diez Campelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Higher-Risk</keyword>
  <keyword>Retinoic Acid Receptor Alpha (RARA) positive</keyword>
  <keyword>Newly Diagnosed</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

